119 related articles for article (PubMed ID: 22186617)
41. Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.
Faller BA; Burtness B
Biologics; 2009; 3():419-28. PubMed ID: 19774209
[TBL] [Abstract][Full Text] [Related]
42. Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer.
Saif MW; Lee Y; Kim R
Ther Adv Med Oncol; 2012 Nov; 4(6):341-6. PubMed ID: 23118809
[TBL] [Abstract][Full Text] [Related]
43. Emerging therapies in pancreas cancer.
Kotowski A; Ma WW
J Gastrointest Oncol; 2011 Jun; 2(2):93-103. PubMed ID: 22811835
[TBL] [Abstract][Full Text] [Related]
44. Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3.
Isherwood J; Arshad A; Chung WY; Runau F; Cooke J; Pollard C; Howells L; Fishwick J; Thompson J; Metcalfe M; Steward W; Dennison A
Ann Transl Med; 2020 Mar; 8(5):172. PubMed ID: 32309319
[TBL] [Abstract][Full Text] [Related]
45. Promising molecular mechanisms responsible for gemcitabine resistance in cancer.
Jia Y; Xie J
Genes Dis; 2015 Dec; 2(4):299-306. PubMed ID: 30258872
[TBL] [Abstract][Full Text] [Related]
46. Small molecule inhibitors in pancreatic cancer.
Sun J; Russell CC; Scarlett CJ; McCluskey A
RSC Med Chem; 2020 Feb; 11(2):164-183. PubMed ID: 33479626
[TBL] [Abstract][Full Text] [Related]
47. Pancreatic cancer genomics.
Chang DK; Grimmond SM; Biankin AV
Curr Opin Genet Dev; 2014 Feb; 24():74-81. PubMed ID: 24480245
[TBL] [Abstract][Full Text] [Related]
48. Cancer pharmacogenomics in children: research initiatives and progress to date.
Rassekh SR; Ross CJ; Carleton BC; Hayden MR
Paediatr Drugs; 2013 Apr; 15(2):71-81. PubMed ID: 23529868
[TBL] [Abstract][Full Text] [Related]
49. Targeted therapies for pancreatic cancer.
Philip PA
Gastrointest Cancer Res; 2008 Jul; 2(4 Suppl):S16-9. PubMed ID: 19343141
[TBL] [Abstract][Full Text] [Related]
50. Pharmacogenomics in Targeted Therapy and Supportive Care Therapies for Cancer.
Talebi Z; Sparreboom A; Colace SI
Methods Mol Biol; 2022; 2547():47-61. PubMed ID: 36068460
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic antibodies for the treatment of pancreatic cancer.
Chames P; Kerfelec B; Baty D
ScientificWorldJournal; 2010 Jun; 10():1107-20. PubMed ID: 20563534
[TBL] [Abstract][Full Text] [Related]
52. The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers.
Yalçin S
Gastrointest Cancer Res; 2009 Sep; 3(5):197-203. PubMed ID: 20084161
[TBL] [Abstract][Full Text] [Related]
53. Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response.
Rosenberg A; Mahalingam D
J Gastrointest Oncol; 2018 Feb; 9(1):143-159. PubMed ID: 29564181
[TBL] [Abstract][Full Text] [Related]
54. Adjuvant therapy for periampullary carcinoma and the significance of histopathological typing: A systematic review.
Duan Z; Zhang Y; Tang Y; Gao R; Bao J; Liang B
Transl Oncol; 2022 Jun; 20():101414. PubMed ID: 35397420
[TBL] [Abstract][Full Text] [Related]
55. Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma.
Fong CYK; Burke E; Cunningham D; Starling N
Gastroenterol Res Pract; 2019; 2019():7135437. PubMed ID: 31582971
[TBL] [Abstract][Full Text] [Related]
56. Targeted therapies for pancreatic cancer.
Danovi SA; Wong HH; Lemoine NR
Br Med Bull; 2008; 87():97-130. PubMed ID: 18753179
[TBL] [Abstract][Full Text] [Related]
57. The molecular targets for the diagnosis and treatment of pancreatic cancer.
Strimpakos AS; Syrigos KN; Saif MW
Gut Liver; 2010 Dec; 4(4):433-49. PubMed ID: 21253292
[TBL] [Abstract][Full Text] [Related]
58. Targeted Approach Succeeds in Pancreatic Cancer.
Cancer Discov; 2020 Jun; 10(6):753. PubMed ID: 32273294
[TBL] [Abstract][Full Text] [Related]
59. New Therapy Options for Neuroendocrine Carcinoma of the Pancreas-The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo.
Buchholz M; Strotmann J; Majchrzak-Stiller B; Hahn S; Peters I; Horn J; Müller T; Höhn P; Uhl W; Braumann C
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681665
[TBL] [Abstract][Full Text] [Related]
60. Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy.
Leylek O; Honeywell ME; Lee MJ; Hemann MT; Ozcan G
bioRxiv; 2023 Nov; ():. PubMed ID: 37873383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
